DALACIN 10 mg/ml liuos iholle Suomi - suomi - Fimea (Suomen lääkevirasto)

dalacin 10 mg/ml liuos iholle

orifarm oy - clindamycini phosphas - liuos iholle - 10 mg/ml - klindamysiini

Rogaine 50 mg/ml liuos iholle Suomi - suomi - Fimea (Suomen lääkevirasto)

rogaine 50 mg/ml liuos iholle

paranova oy - minoxidil - liuos iholle - 50 mg/ml - minoksidiili

CORTACARE 0.584 mg/ml sumute iholle, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

cortacare 0.584 mg/ml sumute iholle, liuos

ecuphar nv - hydrocortisoni aceponas - sumute iholle, liuos - 0.584 mg/ml - hydrokortisoniaseponaatti

ESKATA 685 mg liuos iholle Suomi - suomi - Fimea (Suomen lääkevirasto)

eskata 685 mg liuos iholle

fgk representative service gmb fgk representative service gmb - vety peroxidum - liuos iholle - 685 mg - vetyperoksidi

BETNOVAT SCALP 1 mg/ml liuos iholle Suomi - suomi - Fimea (Suomen lääkevirasto)

betnovat scalp 1 mg/ml liuos iholle

paranova oy - betamethasoni valeras - liuos iholle - 1 mg/ml - beetametasoni

Dalacin 10 mg/ml emulsio iholle Suomi - suomi - Fimea (Suomen lääkevirasto)

dalacin 10 mg/ml emulsio iholle

orifarm oy - clindamycin phosphate - emulsio iholle - 10 mg/ml - klindamysiini

Dalacin 10 mg/ml emulsio iholle Suomi - suomi - Fimea (Suomen lääkevirasto)

dalacin 10 mg/ml emulsio iholle

paranova oy - clindamycin phosphate - emulsio iholle - 10 mg/ml - klindamysiini

Amlodipine / Valsartan Mylan Euroopan unioni - suomi - EMA (European Medicines Agency)

amlodipine / valsartan mylan

mylan pharmaceuticals limited - amlodipiini besilaatti, valsartaanin - verenpainetauti - reniini-angiotensiinijärjestelmään vaikuttavat aineet - essentiaalisen hypertension hoito. amlodipiini/valsartaani mylan on tarkoitettu aikuisille, joiden verenpaine ei laske riittävästi yksinomaan amlodipiinilla tai valsartaanilla.

Azacitidine Mylan Euroopan unioni - suomi - EMA (European Medicines Agency)

azacitidine mylan

mylan ireland limited - atsakitidiini - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiset aineet - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Euroopan unioni - suomi - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogreelibesilata - peripheral vascular diseases; stroke; myocardial infarction - antitromboottiset aineet - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segmentin nousua akuutti sydäninfarkti, yhdessä asa lääketieteellisesti hoitoa saaneilla potilailla oikeutettu liuotushoito. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. lisätietoja, katso kohta 5.